Sponaas A M, Loveland B, Simpson E
MRC Clinical Research Centre, Harrow, Middlesex, U.K.
Immunology. 1988 Feb;63(2):233-9.
F9 embryonal carcinoma cells (EC) grow as tumours in their strain of origin, 129/Sv, but can be rejected by mouse strains differing at the H-2 and/or non-H-2 loci. The presence of H-2 class I and/or minor H antigens on F9 and other EC cells is implied by (i) the rejection of EC cells by mice immunized with appropriate H-2 class I transfectants, and (ii) the ability of appropriate EC cells to prime mice for second-set in vivo skin-graft rejection responses to H-Y, and secondary MLC responses to multiple minor H antigens. However, EC cells express no H-2 class I antigens in vitro, and for in vivo rejection by T-cell responses directed either at allogeneic class I molecules or at minor H antigens restricted by self class I molecules, one would need to postulate that EC cells growing in vivo could express sufficient class I antigens for recognition by T cells. In the course of investigating this question, we found evidence for class I expression but also evidence for an additional antigen(s), shared by EC and tumour cells and recognized in a non-MHC-restricted manner.
F9胚胎癌细胞(EC)在其起源品系129/Sv中会形成肿瘤,但会被H-2和/或非H-2位点不同的小鼠品系排斥。F9细胞和其他EC细胞上存在H-2 I类分子和/或次要组织相容性抗原可通过以下两点推断:(i)用合适的H-2 I类转染细胞免疫的小鼠可排斥EC细胞;(ii)合适的EC细胞能够使小鼠对H-Y产生体内二次皮肤移植排斥反应,并对多种次要组织相容性抗原产生二次混合淋巴细胞反应。然而,EC细胞在体外不表达H-2 I类抗原,并且对于由针对同种异体I类分子或由自身I类分子限制的次要组织相容性抗原的T细胞反应介导的体内排斥反应,人们需要假定体内生长的EC细胞能够表达足够的I类抗原以供T细胞识别。在研究这个问题的过程中,我们发现了I类分子表达的证据,但也发现了一种额外抗原的证据,这种抗原由EC细胞和肿瘤细胞共享,并且是以非MHC限制的方式被识别的。